Relief Therapeutics Holding Stock Price To Book

RLFTF Stock  USD 3.45  0.15  4.17%   
Relief Therapeutics Holding fundamentals help investors to digest information that contributes to Relief Therapeutics' financial success or failures. It also enables traders to predict the movement of Relief OTC Stock. The fundamental analysis module provides a way to measure Relief Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Relief Therapeutics otc stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Relief Therapeutics Holding OTC Stock Price To Book Analysis

Relief Therapeutics' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

 = 

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Current Relief Therapeutics Price To Book

    
  0.70 X  
Most of Relief Therapeutics' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Relief Therapeutics Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Competition

Based on the latest financial disclosure, Relief Therapeutics Holding has a Price To Book of 0.705 times. This is 97.25% lower than that of the Healthcare sector and 88.33% lower than that of the Biotechnology industry. The price to book for all United States stocks is 92.59% higher than that of the company.

Relief Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Relief Therapeutics' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Relief Therapeutics could also be used in its relative valuation, which is a method of valuing Relief Therapeutics by comparing valuation metrics of similar companies.
Relief Therapeutics is currently under evaluation in price to book category among its peers.

Relief Fundamentals

About Relief Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Relief Therapeutics Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relief Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relief Therapeutics Holding based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Relief OTC Stock

Relief Therapeutics financial ratios help investors to determine whether Relief OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Relief with respect to the benefits of owning Relief Therapeutics security.